Zum Hauptinhalt springen
xMedica

NCT07415031ClinicalTrials.gov

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC)…

Phase 2170 Teilnehmende gesucht101 Studienzentren21 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-17; recorded start 2026-05-06
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Mirati Therapeutics Inc.)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 100 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 170 participants (target), run at 101 sites, across 21 countries.

How this score is built
  • Enrolment21/40

    170 participants (target)

  • Site count23/25

    100 sites

  • Country count15/15

    20 countries

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale4/10

    Mirati Therapeutics Inc. has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Erkrankungen

  • Solid Tumors

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. * Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: * Participant is not eligible for study treatment per the parent study eligibility criteria. * Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study. * Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 2
ZuteilungNicht zutreffend
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungNONE (0)
Teilnahme170 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Mirati Therapeutics Inc. Sponsor

Studienarme und Interventionen

  • Arm A1EXPERIMENTAL
  • Arm A2EXPERIMENTAL
  • Arm B1EXPERIMENTAL
  • Arm B2EXPERIMENTAL
  • Arm B3EXPERIMENTAL
  • Arm B4EXPERIMENTAL
  • Arm C1EXPERIMENTAL
  • Arm C2EXPERIMENTAL
  • Arm C3EXPERIMENTAL
  • Arm C4EXPERIMENTAL

Interventionen

  • Arzneimittel Adagrasib

    Specified dose on specified days

  • Arzneimittel Cetuximab

    Specified dose on specified days

  • Arzneimittel Docetaxel

    Specified dose on specified days

  • Arzneimittel Fluorouracil

    Specified dose on specified days

  • Arzneimittel Irinotecan

    Specified dose on specified days

  • Arzneimittel Leucovorin

    Specified dose on specified days

  • Arzneimittel Oxaliplatin

    Specified dose on specified days

  • Arzneimittel Pembrolizumab

    Specified dose on specified days

  • Arzneimittel Pemetrexed

    Specified dose on specified days

Endpunkte

  1. Primärer Endpunkt

    Number of Participants With Adverse Events (AEs)

    Zeitrahmen Up to 90 days from last dose or study discontinuation

  2. Primärer Endpunkt

    Number of Participants With AEs Leading to Treatment Discontinuation

    Zeitrahmen Up to 90 days from last dose or study discontinuation

  3. Primärer Endpunkt

    Number of Participants With Serious Adverse Events (SAEs)

    Zeitrahmen Up to 90 days from last dose or study discontinuation

  4. Primärer Endpunkt

    Number of Participants With AEs Leading to Death

    Zeitrahmen Up to 90 days from last dose or study discontinuation

Daten

Daten
Startdatum6. Mai 2026 (tatsächlich)
Primärer Abschluss16. Februar 2028 (geschätzt)
Abschluss16. Februar 2028 (geschätzt)
Erstveröffentlichung17. Februar 2026 (tatsächlich)
Zuletzt aktualisiert12. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtNovember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

81 Studienzentren rekrutieren

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Local Institution - 0093St LeonardsNew South WalesZurückgezogen

Belgium

Belgium
EinrichtungStadtBundesland oder RegionStatus
AZ Maria MiddelaresGhentRekrutiert

Brazil

Brazil
EinrichtungStadtBundesland oder RegionStatus
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Clinical OncologySão PauloRekrutiert
Fundacao Antonio Prudente - AC Camargo Cancer CenterSão PauloRekrutiert

Canada

Canada
EinrichtungStadtBundesland oder RegionStatus
BC Cancer - VancouverVancouverBritish ColumbiaRekrutiert

China

China
EinrichtungStadtBundesland oder RegionStatus
Local Institution - 0037BeijingBeijing MunicipalityZurückgezogen
Local Institution - 0038ChangshaHunanZurückgezogen
Local Institution - 0040ChengduSichuanZurückgezogen
Local Institution - 0044HangzhouZhejiangZurückgezogen
Local Institution - 0039JinanShandongZurückgezogen
Local Institution - 0047LinyiShandongZurückgezogen
Local Institution - 0048NanchangJiangxiZurückgezogen
Local Institution - 0046NanjingJiangsuZurückgezogen
Local Institution - 0043ShanghaiShanghai MunicipalityZurückgezogen
Local Institution - 0049ShenyangLiaoningZurückgezogen
Local Institution - 0041Xi'anZurückgezogen
Local Institution - 0045XiamenFujianZurückgezogen
Local Institution - 0042ZhengzhouHenanZurückgezogen

France

France
EinrichtungStadtBundesland oder RegionStatus
ICO PapinAngersMaine-et-LoireRekrutiert
Chu Jean MinjozBesançonDoubsRekrutiert
Hospices Civils de Lyon - Hopital Louis PradelBronRhôneRekrutiert
Centre Hospitalier Intercommunal de CréteilCréteilRekrutiert
L Hopital Nord OuestGleizéRhôneRekrutiert
Chu Grenoble AlpesLa TroncheIsèreRekrutiert
Assistance Publique Hôpitaux de Marseille - Hôpital NordMarseilleRekrutiert
Centre Hospitalier Universitaire de Nice - Hopital PasteurNiceAlpes-MaritimesRekrutiert
Centre Antoine-LacassagneNiceAlpes-MaritimesRekrutiert
Groupe hospitalier Paris saint JosephParisÎle-de-France RegionRekrutiert
CHU Bordeaux Haut-LevequePessacAquitaineRekrutiert
Local Institution - 0051PoitiersVienneZurückgezogen
Centre Hospitalier de Cornouaille Quimper - ConcarneauQuimperRekrutiert
Institut de Cancérologie de l'OuestSaint-HerblainLoire-AtlantiqueRekrutiert
Hôpital Nord Guillaume-et-René-Laennec / CHU de NantesSaint-HerblainLoire-AtlantiqueRekrutiert
Hôpital d'Instruction des Armées BéginSaint-MandéRekrutiert
Nouvel Hôpital Civil (NHC)StrasbourgAlsaceRekrutiert
Centre Hospitalier Régional Universitaire de Tours - Hôpital BretonneauToursRekrutiert

Germany

Germany
EinrichtungStadtBundesland oder RegionStatus
Klinikum NeuperlachMünchenRekrutiert

Greece

Greece
EinrichtungStadtBundesland oder RegionStatus
Alexandra General Hospital of AthensAthensAttikíRekrutiert
Metropolitan HospitalAttikiRekrutiert
Theagenio HospitalThessalonikiKentrikí MakedoníaRekrutiert

Hungary

Hungary
EinrichtungStadtBundesland oder RegionStatus
Orszagos Koranyi Pulmonologiai IntezetBudapestRekrutiert
Orszagos Onkologiai IntezetBudapestRekrutiert

Israel

Israel
EinrichtungStadtBundesland oder RegionStatus
Bnai Zion Medical CenterHaifaRekrutiert
Shaare Zedek Medical CenterJerusalemJerusalemRekrutiert
Tel Aviv Sourasky Medical Center - Oncology - Hematology/OncologyTel AvivRekrutiert

Italy

Italy
EinrichtungStadtBundesland oder RegionStatus
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'OrsolaBolognaRekrutiert
Azienda Ospedaliera Universitaria CareggiFlorenceTuscanyRekrutiert
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"MeldolaEmilia-RomagnaRekrutiert
Istituto Europeo di Oncologia IRCCSMilanRekrutiert
Istituto Europeo di Oncologia IRCCSMilanRekrutiert

51 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 27. Oktober 2026

    Studienzentrum entfernt

    1 site removed (101 total)

    102101

  2. 9. Oktober 2026

    Studienzentrum hinzugefügt

    2 sites added (102 total)

    100102

  3. 18. August 2026

    Studienzentrum entfernt

    1 site removed (100 total)

    101100

  4. 27. Juli 2026

    Studienzentrum hinzugefügt

    1 site added (101 total)

    100101